Primo Nery Lara, Jr., M.D. for UC Davis Health

Primo Nery Lara, Jr., M.D.

Director, UC Davis Comprehensive Cancer Center

Executive Associate Dean for Cancer Programs

Professor of Medicine

To see if Primo Nery Lara, Jr. is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).





Internal Medicine

Locations and Contact

UC Davis Comprehensive Cancer Center

UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817

Get Directions

Phone: 916-734-5959

Additional Numbers

Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

I practice compassionate, evidence-based, and innovative care for people with cancer with the goal of improving their outcomes and quality of life.

Clinical Interests

Dr. Lara is a medical oncologist and clinician scientist who has expertise in genitourinary and thoracic malignancies. He is also an expert in cancer clinical trial design and conduct, having successfully led investigational trials from phase I to phase III.

Research/Academic Interests

Dr. Lara's research is focused on investigational new approaches to treat, control, or cure cancer of the genitourinary tract and lung.


Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Undergraduate School

B.S., Biology, University of the Philippines, Quezon City, Philippines 1987

Medical School

M.D., University of the Philippines College of Medicine, Manila, Philippines 1992


Internal Medicine, Rush Presbyterian-St Luke's Medical Center, Chicago IL 1993-1994


Multi-Departmental Rotation, University of the Philippines, Manila, Philippines 1991-1992


Internal Medicine, Rush Presbyterian-St Luke's Medical Center, Chicago IL 1994-1996


Hematology-Oncology, UC Davis School of Medicine, Sacramento CA 1996-1999

Best Doctors, SacTown Magazine, 2021

Best Doctors, Sacramento Magazine, 2020

Named one of the nation's Best Doctors in Oncology, 2011-present (Best Doctors Inc./Sacramento Magazine), 2021

Sacramento Magazine’s Top 300 Most Powerful Business Leaders, 2019

Faculty Research Award, UC Davis School of Medicine, Department of Internal Medicine, 2018

Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. J Clin Oncol. 2023 Feb 1;41(4):871-880. doi:10.1200/JCO.21.02947. Epub 2022 Oct 18. PMID:36256912.

Yang JC, Xu P, Ning S, Wasielewski LJ, Adomat H, Hwang SH, Morisseau C, Gleave M, Corey E, Gao AC, Lara PN Jr, Evans CP, Hammock BD, Liu C. Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene. 2023 Feb;42(9):693-707. doi:10.1038/s41388-022-02566-6. Epub 2023 Jan 3. PMID:36596844.

Sadeghi S, Quinn D, Dorff T, Pal S, Groshen S, Tsao-Wei D, Parikh R, Devitt M, Parikh M, Jackovich A, Ruel N, Vogelzang N, Burgess E, Siddiqi I, Gill IS, Lara PN, Dreicer R, Gill PS. EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. J Clin Oncol. 2023 Jan 20;41(3):640-650. doi:10.1200/JCO.21.02923. Epub 2022 Aug 19. PMID:35984996.

Gulati S, Lara PN. Immune Checkpoint Inhibitors in the Pre-operative Setting and Impact on the Primary Renal Tumor. Kidney Cancer. 2022 Dec 29;6(4):201-203. doi:10.3233/KCA-220019. PMID:36726555.

Cacciamani GE, Barzi A, Eppler MB, Lara PN Jr, Pan CX, Bhanvadia SK, Gill P, Aron M, Gill I, Sadeghi S. The Impact of Facility Surgical Caseload Volumes on Survival Outcomes in Patients Undergoing Radical Cystectomy. Cancers (Basel). 2022 Dec 3;14(23):5984. doi:10.3390/cancers14235984. PMID:36497466.

Woo XY, Srivastava A, Mack PC, Graber JH, Sanderson BJ, Lloyd MW, Chen M, Domanskyi S, Gandour-Edwards R, Tsai RA, Keck J, Cheng M, Bundy M, Jocoy EL, Riess JW, Holland W, Grubb SC, Peterson JG, Stafford GA, Paisie C, Neuhauser SB, Karuturi RKM, George J, Simons AK, Chavaree M, Tepper CG, Goodwin N, Airhart SD, Lara PN, Openshaw TH, Liu ET, Gandara DR, Bult CJ. A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer. Cancer Res. 2022 Nov 15;82(22):4126-4138. doi:10.1158/0008-5472.CAN-22-0948. PMID:36069866.

Leibrandt RC, Tu MJ, Yu AM, Lara PN, Parikh M. ATR Inhibition in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022 Nov 4:S1558-7673(22)00223-3. doi:10.1016/j.clgc.2022.10.016. Epub ahead of print. PMID:36604210.

Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022 Nov 2;82(21):3888-3902. doi:10.1158/0008-5472.CAN-22-1123. PMID:36251389.

Parikh M, Lara PN. Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer. Kidney Cancer. 2022 Aug 4;6(2):105-107. doi:10.3233/KCA-229003. PMID:36212798.

For a comprehensive list of Dr. Lara's publications, please click here.